Reslizumab Disease Interactions

Anaphylaxis to reslizumab was reported in 0.3% of asthma patients in clinical studies. These events were observed during or within 20 minutes after completion of the infusion and reported as early as the second dose of therapy. Patients should be observed for an appropriate period of time after reslizumab administration. If severe systemic reactions, including anaphylaxis, occur, stop administration immediately and provide appropriate medical treatment. Discontinue reslizumab use permanently if the patient experiences signs or symptoms of anaphylaxis.

There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors. Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated. Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.